112 related articles for article (PubMed ID: 30384408)
1. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
El-Behaedi S; Landsman R; Rudloff M; Kolyvas E; Albalawy R; Zhang X; Bera T; Collins K; Kozlov S; Alewine C
Toxins (Basel); 2018 Oct; 10(11):. PubMed ID: 30384408
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
Alewine C; Ahmad M; Peer CJ; Hu ZI; Lee MJ; Yuno A; Kindrick JD; Thomas A; Steinberg SM; Trepel JB; Figg WD; Hassan R; Pastan I
Clin Cancer Res; 2020 Feb; 26(4):828-836. PubMed ID: 31792036
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes.
Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C
Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204
[TBL] [Abstract][Full Text] [Related]
5. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
6. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q; Ghafoor A; Mian I; Rathkey D; Thomas A; Alewine C; Sengupta M; Ahlman MA; Zhang J; Morrow B; Steinberg SM; Pastan I; Hassan R
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611684
[TBL] [Abstract][Full Text] [Related]
7. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
Liu W; Tai CH; Liu X; Pastan I
Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
[TBL] [Abstract][Full Text] [Related]
8. Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK; Liu W; Leshem J; King E; Kozlov S; Pastan I
J Immunother; 2019 May; 42(4):119-125. PubMed ID: 30933045
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
10. Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins.
Antignani A; Segal D; Simon N; Kreitman RJ; Huang D; FitzGerald DJ
Oncogene; 2017 Aug; 36(35):4953-4962. PubMed ID: 28436946
[TBL] [Abstract][Full Text] [Related]
11. Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.
Pegna GJ; Lee MJ; Peer CJ; Ahmad MI; Venzon DJ; Yu Y; Yuno A; Steinberg SM; Cao L; Figg WD; Donahue RN; Hassan R; Pastan I; Trepel JB; Alewine C
Cancer Med; 2023 Feb; 12(4):4236-4249. PubMed ID: 36208017
[TBL] [Abstract][Full Text] [Related]
12. Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity.
Zheng Z; Okada R; Kobayashi H; Nagaya T; Wei J; Zhou Q; Lee F; Bera TK; Gao Y; Kuhlman W; Tai CH; Pastan I
Mol Cancer Ther; 2020 Mar; 19(3):812-821. PubMed ID: 31871266
[TBL] [Abstract][Full Text] [Related]
13. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
[TBL] [Abstract][Full Text] [Related]
15. Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Mazor R; King E; Pastan I
Cell Immunol; 2018 Dec; 334():38-41. PubMed ID: 30213644
[TBL] [Abstract][Full Text] [Related]
16. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Zhang Y; Xiang L; Hassan R; Pastan I
Proc Natl Acad Sci U S A; 2007 Oct; 104(43):17099-104. PubMed ID: 17940013
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.
Alewine C; Xiang L; Yamori T; Niederfellner G; Bosslet K; Pastan I
Mol Cancer Ther; 2014 Nov; 13(11):2653-61. PubMed ID: 25239937
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
Onda M; Willingham M; Wang QC; Kreitman RJ; Tsutsumi Y; Nagata S; Pastan I
J Immunol; 2000 Dec; 165(12):7150-6. PubMed ID: 11120846
[TBL] [Abstract][Full Text] [Related]
20. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
